Background: Venous thromboembolism (VTE) is a complication in children with
| INTRODUCTION
The population scale incidence of pediatric venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, has been estimated to be 0.07 to 0.95 per 10 000 children. [1] [2] [3] The incidence of VTE is increasing across all pediatric populations; however, pediatric VTE is most common among infants and adolescents. 4 Most pediatric VTEs occur among children with at least 1 complex chronic medical condition who are admitted to a tertiary care pediatric hospital. 1,2,4,5 The estimated incidence of VTE among hospitalized children is 40 to 53 per 10 000. 4, 5 Chronic pediatric heart diseases (CPHD), including congenital heart disease, cardiomyopathy (acquired or congenital), conduction disorders (acquired or congenital), and acquired chronic cardiac conditions, are associated with the highest rate of VTE development in children. 4, 5 The reported incidence of extracardiac thrombosis in patients aged 0 to 17 years with cardiomyopathy or congenital heart disease is approximately 1%, with a higher frequency in patients suffering from cardiomyopathy (3.4%-23.1%). 6, 7 Although the relationship of cardiomyopathy and congenital heart disease to VTE development in pediatric patients has been described, the contribution of other CPHD to VTE development has not been well defined.
It is estimated that between 14% and 29% of all inpatient childhood VTEs occur in patients with CPHD. 1,2,4,5 CPHD has been associated with the second-highest rate of hospital-acquired VTE among all complex chronic medical conditions in children. 8 Pediatric cardiac surgery has been associated with an increased risk of VTE, with a reported incidence of up to 11.4%. 9, 10 Children with single-ventricle physiology cardiac lesions seem to be at even higher risk for VTE development following cardiac surgery. 11 Age, heart transplantation, unscheduled intensive care admissions, extracorporeal membrane oxygenation (ECMO), and cardiopulmonary bypass are all factors associated with increased VTE risk in relation to pediatric cardiac surgery. VTE associated with pediatric cardiac surgery has been shown to lead to longer intensive care and hospital stays, increased risk of cardiac arrest, earlier reoperation or percutaneous cardiac catheter reintervention, and increased in-hospital mortality rates. 9, [11] [12] [13] A more thorough understanding of the epidemiology and risk factors associated with VTE development in CPHD is an essential next step toward prevention and management of this life-threatening complication. Although information exists on VTE risk for children with CPHD, many of the published studies are small, retrospective, and inadequately powered to assess the potential impact of noncardiac acute and chronic comorbidities on VTE risk. The impact of noncardiac complex chronic conditions (ncCCCs), recent cardiac or noncardiac surgery, acute trauma, or the presence of acute acquired cardiac conditions on the likelihood of VTE in CPHD may lead to the identification of high-risk groups of children who are most likely to benefit from thromboprophylactic anticoagulation.
In this study, we used an administrative data set to examine VTE prevalence, estimate the health care burden, and delineate risk factors associated with VTE in a large cohort of children with CPHD. We hypothesized that acute and chronic comorbidities would increase the likelihood of VTE and that children with VTE would have higher health care utilization and expenditures than children without VTE. 
| MATERIALS AND METHODS

| Data source
| Study population
Children aged 0 to 17 years of age at the time of their initial CPHD diagnostic code were identified for inclusion if they also had obtainable information on health plan enrollment and outpatient pharmaceutical claims. CPHD was defined using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes for cardiomyopathies (acquired or congenital), single-ventricle physiology congenital heart disease, 2-ventricle physiology congenital heart disease, conduction disorders and dysrhythmias (acquired or congenital), and acquired chronic cardiac conditions (Table 1) .
These groupings were not mutually exclusive, and overlap may exist. The ICD-9-CM classifies congenital heart disease by anatomic diagnosis and not by physiologic palliation. Many anatomic diagnoses can be classified as either single-ventricle or 2-ventricle
Essentials
• Venous thromboembolism (VTE) is a known complication in chronic pediatric heart disease (CPHD).
• The effect of certain VTE risk factors on VTE and its health care burden in CPHD is unknown.
• VTE in CPHD is associated with significantly increased health care resource utilization.
• Recent cardiac or noncardiac surgery is a risk factor that infers the highest VTE risk in CPHD.
physiology following palliation. However, several complex congenital heart disease anatomic ICD-9-CM diagnoses may be described with codes that can be associated with either single-or 2-ventricle physiology following palliation (ie, 745.11, Double-outlet right ventricle Inpatient ICD-9-CM codes for CPHD were considered valid, as previously described. 15 Outpatient codes without a matching inpatient diagnosis were considered only if 2 or more codes were recorded at least 30 days apart. Children with an initial CPHD diagnosis reported after June 30, 2013, were excluded to enable a 6-month accrual window for the event data described below. To reduce the likelihood of capturing preexisting cardiac diagnoses, children needed to be continuously enrolled for at least 6 months prior to the initial claim with a CPHD diagnosis (except for infants) and at least 6 months after the claim with a CPHD diagnosis (unless an in-hospital death was reported); otherwise, they were excluded.
| Venous thromboembolism
Children included in the study were categorized into the VTE group if an ICD-9-CM diagnosis code for VTE or CPT code for a VTEassociated procedure was found concomitantly with their first claim with a CPHD diagnosis or during the following 6-month follow-up period. 4, 5, 15 Consistent with previous studies using administrative data, all inpatient VTE codes were considered valid; however, outpatient codes without a matching inpatient diagnostic code were included only if there was evidence of a filled anticoagulant prescription within 90 days following the VTE diagnosis.
15,16
| Comorbid conditions
All ncCCC diagnoses were ascertained using ICD-9-CM codes and were included if they occurred between 3 months prior to the first claim with a CPHD diagnosis and 6 months after that claim (irrespective of VTE diagnosis in that time frame), as previously described.
15,17
The ncCCCs included neuromuscular, renal, respiratory, gastrointestinal, hematology and immunodeficiency, metabolic, genetic, and malignant chronic conditions. Again, all inpatient codes were considered valid, whereas outpatient codes without a corresponding inpatient diagnosis were considered valid only if 2 or more codes were recorded at least 30 days apart within the 9-month reporting range.
Subject accrual began April 1, 2003, to account for the prediagnosis 3-month comorbidity time frame.
Acute-onset comorbidities were ascertained during the 3 months prior to VTE diagnosis or 3 months prior and 6 months after CPHD diagnosis in those lacking a VTE diagnosis. 5 They were organized into trauma, noncardiac surgery, cardiac procedure/surgery, heart transplantation, postoperative ECMO/cardiopulmonary bypass, infections, and acquired acute cardiovascular conditions. These are major risk factors known to be associated with pediatric VTE in general as well as VTE in CPHD patients. 5,9 ICD-9-CM codes indicative of trauma were used, as previously published (Table 1) . 5, 15, 18 Noncardiac surgery was identified using diagnosis-related group codes, as previously described. 15, 16 Heart transplantation, ECMO, and acquired acute cardiovascular conditions were identified using ICD-9-CM diagnosis codes (see Table 1 ). Cardiac procedures/surgery were identified using ICD-9-CM and CPT codes (Table S1) Research and Quality 19 was used to identify infections, with minor modifications as described in Table 1 and as reported previously.
15
For the purposes of this study, all ICD-9-CM "V" codes were ignored due to their known lack of specificity. 
| Statistics
The distributions of demographic and clinical characteristics of children with CPHD with and without a VTE diagnosis were compared using chi-square and 2-tailed Student's t-tests. The prevalence of VTE for each CPHD category and for children with heart transplant and ECMO was also calculated. Unadjusted and adjusted odds ratios and 95% confidence intervals (CIs) were used to assess the association between demographic and clinical characteristics with VTE among children with CPHD. The variables included in the initial multivariable models were age at first CPHD claim, ncCCC, cardiac surgery, noncardiac surgery, trauma, infection, and acquired acute cardiovascular conditions. Statistically significant interactions were noted for cardiac surgery and ncCCCs, trauma, infection, and other noncardiac surgery. Due to this finding, final models were stratified by cardiac surgery. SAS Version 9.4 (Cary, NC) and Stata 14 (College Station, TX) were used for analyses. P < 0.05 was considered statistically significant.
| RESULTS
| Demographics
Between April 1, 2003, and June 30, 2013, there were 120 884 children 0 to 17 years of age with a CPHD diagnosis ( Table 2) . VTE occurred in 957 (0.8%) of these children, 802 (83.8%) of which were isolated DVT and 155 (16.2%) were pulmonary embolisms with or without concomitant DVT. Although the age distribution differed for children with and without VTE (P < 0.0001), the mean age of the groups was not significantly different. The proportion of males was higher in children with VTE compared to those without (60.8% vs.
52.5%; P < 0.0001). In-hospital mortality was considerably higher in children with VTE vs. those without (10.8% vs. 1.3%; P < 0.0001).
The prevalence of VTE increased from 0.19% (2003) to 1.63%
(2013), which is consistent with previously reported overall pediatric VTE prevalence data.
With the exception of the Conduction Disorders and
Dysrhythmias category, the distribution of each CPHD type was significantly different for children with and without VTE ( Table 2 ).
The prevalence of VTE in children with single-ventricle physiology was 2.3%, whereas the prevalence of VTE in other categories ranged from 0.5% to 1.9% (Figure 1 
| Multivariable analysis
Age, ncCCC, recent trauma, recent infection, recent noncardiac surgery, and acquired acute cardiovascular conditions were significantly associated with VTE after stratifying for the presence or absence of recent cardiac surgery ( We further examined differences in the type of chronic conditions among patients with and without VTE, stratified by recent cardiac surgery (Table 4 ). All of the ncCCCs assessed in this analysis were significantly associated with VTE in the cohort of patients who did not have recent cardiac surgery. For patients with ncCCC and recent cardiac surgery, significant VTE association was seen with all ncCCCs except gastrointestinal disease (P = 0.09) and malignancy (P = 0.22) ( Table 4) .
TA B L E 4 Distribution of noncardiac CCC types stratified for recent cardiac surgery
Recent cardiac surgery = yes Recent cardiac surgery = no
VTE (n = 511) n (%)
No VTE (n = 4106) n (%) P value
VTE (n = 446) n (%)
No VTE (n = 115 821) n (%) P value 
| Health care utilization and expenditures
All measures of health care utilization were higher for patients with VTE vs. those without VTE (Table 5 ). For example, children with VTE had over 3.5-times more admissions (2.2 vs. 0.6; P < 0.0001) and they stayed in the hospital more than 6-times longer (55.1 vs. 8.7 days; P < 0.0001). Likewise, children with VTE had 2.5 times the number of outpatient visits than those without VTE (28.1 vs. 11.2; P < 0.0001) and filled almost 3 times more prescriptions (13.3 vs. 4.7; P < 0.0001). After adjustment, VTE diagnosis was associated with more than 2-fold higher total mean expenditures compared to the non-VTE group ($93 780 vs.
$42 725; P < 0.0001).
To determine if these utilization patterns were driven by the higher acuity of single-ventricle physiology rather than VTE, we confirmed these observations in the single-ventricle subcohort (Table 6 ). Similar to the overall CPHD group, patients with singleventricle physiologywith VTE had 2.5 times more inpatient admissions (2.4 vs. 0.95; P < 0.0001), 5.5 times longer hospital stays (80.8
vs. 14.6; P < 0.0001), 1.9 times more outpatient visits (26.6 vs. 14.3; P < 0.0001), and 1.6 times more prescription claims (10.3 vs. 6.3; P < 0.0001). After adjustment, total mean expenditures for children with VTE were 1.5 times those of children without VTE ($195 577 vs. $126 878; P = 0.003).
| DISCUSSION
In this large cohort of children with CPHD, approximately 0.8% were affected by VTE. This is lower than the previously reported VTE prevalence in pediatric heart disease (1.3%-2.4%), but this is likely reflective of the inclusion of lower-risk CPHD conditions such as conduction disorders. 2,4,6,7 The observed prevalence was similar to previous reports for specific CPHD conditions (ie, single-ventricle and cardiomyopathy). 6, 7 We found that conditions reflecting single-ventricle physiology had the highest prevalence of CPHDassociated VTE (2.3%), whereas previous reports suggest that children with cardiomyopathy are most likely to develop VTE. 6, 7 Approximately 65% of children experiencing a VTE also had an ncCCC, which is similar to previous reports on VTE in children with chronic renal disease. 16 All of the co-occurring conditions, including acute conditions and procedures, were significantly associated with VTE, and VTE occurred most frequently in children with an ncCCC and recent surgery (cardiac and noncardiac). The prevalence of VTE was much higher in children with recent cardiac and noncardiac surgery (11.1% and 7.8%, respectively), suggesting that recent surgery poses substantial VTE risk. VTE was also associated with significantly increased in-hospital mortality and higher health care resource utilization and costs, although other unmeasured comorbidities among children with VTE may also influence these parameters.
Over 53% of patients with VTE had a recent cardiac surgery, and 50% had a recent noncardiac surgery in this study. VTE as a complication following surgery has been understood for many years, yet very few data exist on the incidence, risk factors, and outcomes specifically regarding recent cardiac and noncardiac surgery in children with CPHD. 5, 20 There is recent evidence showing that the rate of recognized VTE in congenital heart disease following cardiac surgery is increasing and that it is associated with younger age (<28 days). 21 In our study, recent cardiac surgery seemed to interact with many of the other risk factors, suggesting that it may have accounted for a TA B L E 6 Single-ventricle CPHD patient health care utilization and expenditures with and without VTE (6 mo following first CPHD diagnosis)
VTE (n = 262)
No VTE (n = 11 186) Although in-hospital mortality was significantly higher in patients with CPHD and VTE, it is not possible to determine mortality causes with secondary analyses of claims data. Thus, these observations may reflect that VTEs are more likely among the most critically ill children. However, up to 21% of deaths in CPHD patients undergoing cardiac surgery have been directly attributed to VTE development and higher mortality rates (12.3% vs. 0.8%; P < 0.001) have been described previously in patients with congenital heart disease who develop VTE compared to those that do not.
20,21
This study was designed to detect VTEs that were reported with a concurrent CPHD diagnosis or in the 6 months following the CPHD diagnosis; however, because hemostatic abnormalities may persist, especially in congenital heart disease, late and/or recurrent VTEs may not have been captured in these analyses. 25 The study strategy also excluded the ability to capture recurrent or subsequent VTEs, so the influence of this complication on the utilization data could not be ascertained. Also, the CPHD categories were not mutually exclusive, suggesting that overlap between the groups may exist.
Observational studies are subject to selection bias.
Misclassification in regards to CPHD and/or VTE diagnosis due to insufficient sensitivity and specificity with ICD-9-CM coding systems could result in information bias. 27, 28 To limit this bias, multiple codes, including CPT codes, were used to help discern appropriate CPHD diagnoses and eliminate overlap in the various groups, and multiple diagnostic identifiers were used to aid in identifying VTE, as previously described. 15 It is important to note that this data set is representative of commercially insured individuals and does not include children enrolled in Medicaid.
Thus, our findings may be generalizable only to privately insured children. Also, certain known pediatric VTE risk factors, including thrombophilia and CVC placement, cannot be accurately discerned from claims data. CVCs are often used to care for children with various forms of CPHD and, thus, may play an important role in CPHD-related VTE. As such, residual confounding due to unmeasured confounders may have influenced our results. Future epidemiologic research of CPHD-associated VTE should focus on defining the clinical attributes (ie, CVC type and anatomic location, infections, age, etc.) within the high-risk groups defined here to determine which CPHD patients are most likely to benefit from thromboprophylactic interventions.
In summary, this study demonstrates that VTE in CPHD patients is a life-threatening complication of CPHD that also significantly impacts health care resource utilization and cost. Despite the limitation that confounding for illness severity cannot be completely controlled for in a claims data study, these data reveal important information regarding VTE risk stratification in children with CPHD. In particular, those undergoing surgical procedures, especially cardiac surgery, are at greatest risk for VTE development, which may inform future VTE prevention approaches. These data indicate that children with CPHD who require a surgical procedure, especially with the presence of other comorbid illnesses including ncCCC, may benefit from randomized trials of thromboprophylactic interventions.
ACKNOWLEDGMENTS
BAK is supported by funding from the National Institutes of Health (K08DK103982 and L40DK103299).
RELATIONSHIP DISCLOSURE
BAK received research funding from CSL Behring Foundation and Novo Nordisk A/S unrelated to this study. The other authors state that they have no conflict of interest to report. 
AUTHOR CONTRIBUTIONS
